Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
vTv Therapeutics Inc. (VTVT)
|
Add to portfolio |
|
|
|
| Price: |
$3.44
| | Metrics |
| OS: |
104.6
|
M
| |
|
|
| Market cap: |
$360
|
M
| |
-2345
|
% ROIC
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
($0.24)
| |
|
|
|
BVPS
|
($0.06)
| |
-56.18
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 2.0 | 4.0 | 6.4 | 2.8 | 12.4 | 0.3 | 0.6 | 0.5 |
| Revenue growth | -49.6% | -37.6% | 132.1% | -77.8% | 4172.9% | -54.1% | 22.2% | -66.5% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 2.0 | 4.0 | 6.4 | 2.8 | 12.4 | 0.3 | 0.6 | 0.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 12.4 | 13.3 | 11.0 | 15.1 | 23.0 | 39.6 | 45.0 | 27.2 |
| General and administrative | 12.2 | 12.3 | 7.3 | 8.5 | 9.2 | 11.3 | 9.9 | 9.1 |
| EBIT | -22.5 | -21.7 | -11.9 | -20.9 | -19.8 | -50.7 | -55.0 | -38.1 |
| EBIT margin | -1116.9% | -540.9% | -184.8% | -755.9% | -159.4% | -17416.5% | -8678.2% | -7349.1% |
| Pre-tax income | -24.9 | -17.6 | -12.8 | -21.8 | -23.6 | -53.8 | -55.4 | -41.1 |
| Income taxes | 0.2 | 0.1 | 0.0 | 0.1 | 0.2 | 0.8 | 0.0 | 0.0 |
| Tax rate | | | 0.0% | | | | 0.0% | 0.0% |
| Net income | -19.2 | -13.0 | -8.5 | -17.9 | -8.7 | -16.1 | -16.4 | -27.5 |
| Net margin | -949.7% | -324.3% | -132.5% | -648.1% | -69.6% | -5547.8% | -2579.2% | -5298.3% |
| |
| Diluted EPS | ($0.26) | ($0.21) | ($0.18) | ($0.59) | ($0.69) | ($1.67) | ($1.71) | ($3.32) |
| Shares outstanding (diluted) | 74.9 | 60.7 | 47.1 | 30.3 | 12.4 | 9.7 | 9.5 | 8.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|